Trial Profile
A First-in-Human, Open-Label, Multicenter, Dose-Escalation Phase I Clinical Study of Single-Agent RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs RO-7172508 (Primary) ; RO-7172508 (Primary) ; Obinutuzumab; Tocilizumab
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Roche
- 17 Aug 2020 Status has been changed to discontinued.
- 07 Aug 2019 Status changed from recruiting to discontinued.
- 25 Jun 2019 Planned End Date changed from 15 Jun 2021 to 22 Dec 2020.